Related Experiment Video

Updated: May 13, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Targeting the insulin-like growth factor-1 receptor in human cancer

Alexandre Arcaro1

  • 1Division of Pediatric Hematology/Oncology, Department of Clinical Research, University of Bern Bern, Switzerland.

Frontiers in Pharmacology
|March 26, 2013
PubMed

Insights

The insulin-like growth factor (IGF) signaling pathway is vital in cancer. Targeting the IGF-1 receptor (IGF-1R) with new drugs shows promise in preclinical models and clinical trials for various solid tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The insulin-like growth factor (IGF) signaling system is implicated in human cancer development.
  • Deregulation, including autocrine loops and IGF-1 receptor (IGF-1R) overexpression, is common in various cancers.
  • Epidemiological studies link elevated IGF levels to increased risk of solid tumors like breast, colon, and prostate cancer.

Purpose of the Study:

  • To review the role of the IGF signaling system in human cancer.
  • To discuss current anti-cancer strategies targeting the IGF-1 receptor (IGF-1R).

Main Methods:

  • Review of scientific literature on IGF signaling in cancer.
  • Analysis of anti-cancer strategies targeting IGF-1R, including neutralizing antibodies and small molecule inhibitors.
  • Summary of preclinical and clinical trial data for IGF-1R inhibitors.

Main Results:

  • IGF signaling pathway deregulation is a frequent event in human cancers.
  • Preclinical studies demonstrate anti-tumor activity for agents targeting IGF-1R.
  • Clinical trials are evaluating the safety and efficacy of IGF-1R inhibitors, often in combination therapies.

Conclusions:

  • The IGF signaling system is a critical target in oncology.
  • Targeting the IGF-1 receptor (IGF-1R) with novel agents represents a promising therapeutic strategy.
  • Further research and clinical evaluation are ongoing to optimize IGF-1R-targeted cancer therapies.
Keywords:
IGF-1 receptorcancerclinical trialsinsulin-like growth factormonoclonal antibodytyrosine kinase inhibitor

More Related Videos

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: